151 related articles for article (PubMed ID: 2160796)
1. Comparative studies on the antirhinovirus activity and the mode of action of the rhinovirus capsid binding agents, chalcone amides.
Ninomiya Y; Shimma N; Ishitsuka H
Antiviral Res; 1990 Feb; 13(2):61-74. PubMed ID: 2160796
[TBL] [Abstract][Full Text] [Related]
2. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15,731, 4',6-dichloroflavan, and enviroxime.
Ninomiya Y; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
Antimicrob Agents Chemother; 1985 Apr; 27(4):595-9. PubMed ID: 2988431
[TBL] [Abstract][Full Text] [Related]
3. Antivirus agent, Ro 09-0410, binds to rhinovirus specifically and stabilizes the virus conformation.
Ninomiya Y; Ohsawa C; Aoyama M; Umeda I; Suhara Y; Ishitsuka H
Virology; 1984 Apr; 134(2):269-76. PubMed ID: 6100571
[TBL] [Abstract][Full Text] [Related]
4. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410.
Ishitsuka H; Ninomiya YT; Ohsawa C; Fujiu M; Suhara Y
Antimicrob Agents Chemother; 1982 Oct; 22(4):617-21. PubMed ID: 6295261
[TBL] [Abstract][Full Text] [Related]
5. Molecular basis of drug resistance to new antirhinovirus agents.
Ishitsuka H; Ninomiya Y; Suhara Y
J Antimicrob Chemother; 1986 Oct; 18 Suppl B():11-8. PubMed ID: 3025150
[TBL] [Abstract][Full Text] [Related]
6. Antiviral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses.
Dewindt B; van Eemeren K; Andries K
Antiviral Res; 1994 Sep; 25(1):67-72. PubMed ID: 7811059
[TBL] [Abstract][Full Text] [Related]
7. Studies of rhinovirus resistant to an antiviral chalcone.
Ahmad AL; Dowsett AB; Tyrrell DA
Antiviral Res; 1987 Aug; 8(1):27-39. PubMed ID: 2825590
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers.
Phillpotts RJ; Higgins PG; Willman JS; Tyrrell DA; Lenox-Smith I
J Antimicrob Chemother; 1984 Oct; 14(4):403-9. PubMed ID: 6094423
[TBL] [Abstract][Full Text] [Related]
9. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410.
Yasin SR; al-Nakib W; Tyrrell DA
Antimicrob Agents Chemother; 1990 Jun; 34(6):963-6. PubMed ID: 2168152
[TBL] [Abstract][Full Text] [Related]
10. Synergism between anti-rhinovirus antivirals: various human interferons and a number of synthetic compounds.
Ahmad AL; Tyrrell DA
Antiviral Res; 1986 Jul; 6(4):241-52. PubMed ID: 3017203
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and antirhinovirus activity of 3-(diethylamino)-5-phenylisoxazole derivatives.
Mazzei M; Garzoglio R; Balbi A; Grandi T; De Montis A; Corrias S; La Colla P
Farmaco; 1996 May; 51(5):351-9. PubMed ID: 8767845
[TBL] [Abstract][Full Text] [Related]
12. VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds.
Ledford RM; Patel NR; Demenczuk TM; Watanyar A; Herbertz T; Collett MS; Pevear DC
J Virol; 2004 Apr; 78(7):3663-74. PubMed ID: 15016887
[TBL] [Abstract][Full Text] [Related]
13. Intranasal chalcone, Ro 09-0410, as prophylaxis against rhinovirus infection in human volunteers.
Al-Nakib W; Higgins PG; Barrow I; Tyrrell DA; Lenox-Smith I; Ishitsuka H
J Antimicrob Chemother; 1987 Dec; 20(6):887-92. PubMed ID: 3326874
[TBL] [Abstract][Full Text] [Related]
14. A 'new' generation of more potent synthetic antirhinovirus compounds: comparison of their MICs and their synergistic interactions.
Al-Nakib W; Tyrrell DA
Antiviral Res; 1987 Nov; 8(4):179-87. PubMed ID: 2833156
[TBL] [Abstract][Full Text] [Related]
15. Binding affinities of structurally related human rhinovirus capsid-binding compounds are related to their activities against human rhinovirus type 14.
Fox MP; McKinlay MA; Diana GD; Dutko FJ
Antimicrob Agents Chemother; 1991 Jun; 35(6):1040-7. PubMed ID: 1656851
[TBL] [Abstract][Full Text] [Related]
16. Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.
Andries K; Dewindt B; Snoeks J; Willebrords R
Arch Virol; 1989; 106(1-2):51-61. PubMed ID: 2548460
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and activity of piperazine-containing antirhinoviral agents and crystal structure of SDZ 880-061 bound to human rhinovirus 14.
Oren DA; Zhang A; Nesvadba H; Rosenwirth B; Arnold E
J Mol Biol; 1996 May; 259(1):120-34. PubMed ID: 8648640
[TBL] [Abstract][Full Text] [Related]
18. SDZ 35-682, a new picornavirus capsid-binding agent with potent antiviral activity.
Rosenwirth B; Oren DA; Arnold E; Kis ZL; Eggers HJ
Antiviral Res; 1995 Jan; 26(1):65-82. PubMed ID: 7741522
[TBL] [Abstract][Full Text] [Related]
19. A novel benzonitrile analogue inhibits rhinovirus replication.
Lacroix C; Querol-Audí J; Roche M; Franco D; Froeyen M; Guerra P; Terme T; Vanelle P; Verdaguer N; Neyts J; Leyssen P
J Antimicrob Chemother; 2014 Oct; 69(10):2723-32. PubMed ID: 24948704
[TBL] [Abstract][Full Text] [Related]
20. Comparative antirhinoviral activities of soluble intercellular adhesion molecule-1 (sICAM-1) and chimeric ICAM-1/immunoglobulin A molecule.
Crump CE; Arruda E; Hayden FG
Antimicrob Agents Chemother; 1994 Jun; 38(6):1425-7. PubMed ID: 7916558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
